INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement
View HTML
Toggle Summary Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the
View HTML
Toggle Summary Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Christopher Haqq ,
View HTML
Toggle Summary Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
SOUTH SAN FRANCISCO, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the opening of its Atara
View HTML
Toggle Summary Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas
Findings presented at 23rd Congress of European Hematology Association Tab-cel™ demonstrated durable remissions and encouraging safety profile in patients with EBV+ PTLD who failed first line therapy Median survival in SOT patients was 21.3 months and was not reached in the HCT population after
View HTML
Toggle Summary Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)
SOUTH SAN FRANCISCO, Calif. , June 13, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced publication of new
View HTML
Toggle Summary Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , June 07, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement
View HTML
Toggle Summary Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif. , June 07, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Utpal Koppikar has
View HTML
Toggle Summary Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 29, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover ,
View HTML
Toggle Summary Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association
SOUTH SAN FRANCISCO, Calif. , May 17, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company and its
View HTML